{
    "clinical_study": {
        "@rank": "159741", 
        "arm_group": [
            {
                "arm_group_label": "Arm I (Study I)", 
                "arm_group_type": "Experimental", 
                "description": "Patients apply spironolactone topically to face BID for 4 weeks."
            }, 
            {
                "arm_group_label": "Arm II (Study I)", 
                "arm_group_type": "Placebo Comparator", 
                "description": "Patients apply placebo topically to face BID for 4 weeks."
            }, 
            {
                "arm_group_label": "Arm I (Study II)", 
                "arm_group_type": "Experimental", 
                "description": "Patients apply spironolactone topically to face and body BID for 4 weeks."
            }, 
            {
                "arm_group_label": "Arm II (Study II)", 
                "arm_group_type": "Active Comparator", 
                "description": "Patients receive modified preemptive therapy regimen consisting of skin moisturizer topically BID, sunscreen topically as needed, hydrocortisone topically QD, and doxycycline PO BID for 4 weeks."
            }
        ], 
        "brief_summary": {
            "textblock": "This randomized phase II trial studies how well giving spironolactone works in preventing\n      rash in patients with advanced cancer receiving panitumumab and cetuximab. Spironolactone\n      may prevent endothelial growth factor receptor (EGFR) inhibitor-induced skin rash."
        }, 
        "brief_title": "Spironolactone in Preventing Rash in Patients With Advanced Cancer Receiving Panitumumab and Cetuximab", 
        "condition": [
            "Dermatologic Complications", 
            "Malignant Neoplasm"
        ], 
        "condition_browse": {
            "mesh_term": "Neoplasms"
        }, 
        "detailed_description": {
            "textblock": "PRIMARY OBJECTIVES:\n\n      I. To determine feasibility of the administration of topical spironolactone versus placebo\n      in this patient population. (Study I) II. To further explore the efficacy of the topical\n      spironolactone to prevent/attenuate rash from EGFR inhibitors. (Study II)\n\n      SECONDARY OBJECTIVES:\n\n      I. To explore efficacy of the spironolactone versus placebo. (Study I) II. To describe the\n      efficacy of a Modified Preemptive Therapy Regimen intervention. (Study II) III. To explore\n      the adverse event profile of spironolactone and the Modified Preemptive Therapy Regimen\n      intervention. (Study II) IV. To explore patient reported outcomes of patients using\n      spironolactone and a Modified Preemptive Therapy Regimen intervention. (Study II) V. To\n      explore long term (8 week) effect of the 4 week treatment of spironolactone and a Modified\n      Preemptive Therapy Regimen intervention on EFGR induced rash. (Study II)\n\n      OUTLINE:\n\n      STUDY I: Patients are randomized to 1 of 2 treatment arms.\n\n      ARM I: Patients apply spironolactone topically to face twice daily (BID) for 4 weeks.\n\n      ARM II: Patients apply placebo topically to face BID for 4 weeks.\n\n      STUDY II: Patients are randomized to 1 of 2 treatment arms.\n\n      ARM I: Patients apply spironolactone topically to face and body BID for 4 weeks\n\n      ARM II: Patients undergo modified preemptive therapy regimen consisting of skin moisturizer\n      topically BID, sunscreen topically before going outside, hydrocortisone topically once daily\n      (QD), and doxycycline orally (PO) BID for 4 weeks."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Scheduled to start panitumumab or cetuximab; patients must not have been on the EGFR\n             agent prior to randomization\n\n          -  Ability to reliably apply topical spironolactone/placebo twice a day to the face\n\n          -  Ability to complete questionnaire(s) by themselves or with assistance\n\n          -  For study 2 only, patients must be willing to avoid sun exposure for one month from\n             registration\n\n          -  Creatinine =< 1.5 x upper limit of normal (UNL)\n\n        Exclusion Criteria:\n\n          -  Prior allergic reaction or severe intolerance to spironolactone\n\n          -  Any rash at the time of randomization\n\n          -  Cutaneous metastases\n\n          -  Any other disorder that may predispose to hyperkalemia in the opinion of the treating\n             oncologist\n\n          -  Use of topical corticosteroids at the time of study or their anticipated use in the\n             next 8 weeks; (it is acknowledged that patients may be starting these agents\n             pre-emptively as part of this protocol)\n\n          -  For study 2 only, previous intolerance of sunscreen or any of the other components of\n             the Modified Preemptive Therapy Regimen (a moisturizer or oral doxycycline)"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "80", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "August 27, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01867294", 
            "org_study_id": "RC09C8", 
            "secondary_id": [
                "NCI-2012-01275", 
                "RC09C8"
            ]
        }, 
        "intervention": [
            {
                "arm_group_label": [
                    "Arm I (Study I)", 
                    "Arm I (Study II)"
                ], 
                "description": "Given topically", 
                "intervention_name": "spironolactone", 
                "intervention_type": "Drug", 
                "other_name": [
                    "Aldactone", 
                    "SC 9420", 
                    "SPL"
                ]
            }, 
            {
                "arm_group_label": "Arm II (Study I)", 
                "description": "Given topically", 
                "intervention_name": "placebo", 
                "intervention_type": "Other", 
                "other_name": "PLCB"
            }, 
            {
                "arm_group_label": [
                    "Arm I (Study I)", 
                    "Arm II (Study I)", 
                    "Arm I (Study II)", 
                    "Arm II (Study II)"
                ], 
                "description": "Ancillary studies", 
                "intervention_name": "questionnaire administration", 
                "intervention_type": "Other"
            }, 
            {
                "arm_group_label": "Arm II (Study II)", 
                "description": "Given topically", 
                "intervention_name": "sunscreen", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Arm II (Study II)", 
                "description": "Moisturizer given topically", 
                "intervention_name": "management of therapy complications", 
                "intervention_type": "Procedure", 
                "other_name": "complications of therapy, management of"
            }, 
            {
                "arm_group_label": "Arm II (Study II)", 
                "description": "Given PO", 
                "intervention_name": "doxycycline", 
                "intervention_type": "Drug", 
                "other_name": [
                    "Doxycycline Monohydrate", 
                    "Vibramycin"
                ]
            }, 
            {
                "arm_group_label": "Arm II (Study II)", 
                "description": "Given topically", 
                "intervention_name": "therapeutic hydrocortisone", 
                "intervention_type": "Drug", 
                "other_name": [
                    "Aeroseb-HC", 
                    "Barseb HC", 
                    "Cetacort", 
                    "Cort-Dome", 
                    "Cortef"
                ]
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Doxycycline", 
                "Doxycycline hyclate", 
                "Cortisol succinate", 
                "Hydrocortisone acetate", 
                "Hydrocortisone 17-butyrate 21-propionate", 
                "Hydrocortisone", 
                "Hydrocortisone-17-butyrate", 
                "Spironolactone", 
                "Sunscreening Agents", 
                "Cetuximab"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "lastchanged_date": "May 21, 2014", 
        "location": {
            "facility": {
                "address": {
                    "city": "Phoenix", 
                    "country": "United States", 
                    "state": "Arizona", 
                    "zip": "85054"
                }, 
                "name": "Mayo Clinic Hospital"
            }
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "4", 
        "official_title": "A Two-Part, Phase II Randomized Trial to Explore Topical Spironolactone to Prevent/Attenuate Rash From Epidermal Growth Factor Receptor Inhibitors (Panitumumab and Cetuximab) in Advanced Cancer Patients", 
        "overall_official": {
            "affiliation": "Academic and Community Cancer Research United", 
            "last_name": "Aminah Jatoi", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Active, not recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "December 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "description": "Treatment will be considered feasible if at least 60% of patients complete study intervention.", 
                "measure": "Percentage of patients in the spironolactone arm who complete the 4-week study intervention (Study I)", 
                "safety_issue": "No", 
                "time_frame": "4 weeks"
            }, 
            {
                "description": "The treatment will be considered feasible if at least 50% of patients in the spironolactone arm develop a truncal/extremity rash of any grade at the end of 4 weeks.", 
                "measure": "Incidence of truncal/extremity rash of any grade in patients in the spironolactone arm (Study I)", 
                "safety_issue": "Yes", 
                "time_frame": "4 weeks"
            }, 
            {
                "description": "The treatment will be considered feasible if less than 20% of patients experience a grade 2+ adverse event attributed to spironolactone.", 
                "measure": "Incidence of a grade 2+ adverse event attributed to spironolactone (Study I)", 
                "safety_issue": "Yes", 
                "time_frame": "8 weeks"
            }, 
            {
                "description": "The primary analysis will be descriptive in nature, and will involve an intent-to-treat analysis at the end of week 4. Patients will be categorized dichotomously according to healthcare provider reported grade 2 or worse rash. The absence of any grade 2 or worse rash will be a success and the existence of any such rash will be a failure. Patients who do not complete the 4 week treatment will be considered a failure. Point estimates and 95% confidence limits will be calculated.", 
                "measure": "Efficacy of the spironolactone treatment to prevent/attenuate rash from EGFR inhibitors in this patient population defined as absence of any grade 2 or worse rash (Study II)", 
                "safety_issue": "No", 
                "time_frame": "4 weeks"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01867294"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "Patients will be dichotomously categorized as a success if no rash is reported and a failure if rash exists at the end of 4 weeks. Frequency statistics will be employed to determine the percent of patients receiving efficacious treatment. Point estimates and 95% confidence intervals will be calculated. The success rate will be used to further determine whether to proceed to Stage 2.", 
                "measure": "Efficacy of spironolactone versus placebo measured by the use of the Brief Pictorial Rash Incidence Questionnaire (Study I)", 
                "safety_issue": "No", 
                "time_frame": "4 weeks"
            }, 
            {
                "description": "All secondary endpoints will be reported descriptively using frequency statistics and single sample t-tests. Outcomes with respect to baseline covariates will also be explored.", 
                "measure": "Efficacy of the Modified Preemptive Therapy Regimen, calculated and analyzed analogously to the efficacy of the spironolactone (Study II)", 
                "safety_issue": "No", 
                "time_frame": "4 weeks"
            }, 
            {
                "description": "All secondary endpoints will be reported descriptively using frequency statistics and single sample t-tests. Outcomes with respect to baseline covariates will also be explored.", 
                "measure": "Incidence of healthcare provider reported adverse events(Study II)", 
                "safety_issue": "Yes", 
                "time_frame": "8 weeks"
            }, 
            {
                "description": "All secondary endpoints will be reported descriptively using frequency statistics and single sample t-tests. Outcomes with respect to baseline covariates will also be explored.", 
                "measure": "Patient reported outcomes (Study II)", 
                "safety_issue": "No", 
                "time_frame": "4 weeks"
            }, 
            {
                "description": "All secondary endpoints will be reported descriptively using frequency statistics and single sample t-tests. Outcomes with respect to baseline covariates will also be explored.", 
                "measure": "Long-term effect on EFGR induced rash (Study II)", 
                "safety_issue": "No", 
                "time_frame": "8 weeks"
            }
        ], 
        "source": "Academic and Community Cancer Research United", 
        "sponsors": {
            "collaborator": {
                "agency": "National Cancer Institute (NCI)", 
                "agency_class": "NIH"
            }, 
            "lead_sponsor": {
                "agency": "Academic and Community Cancer Research United", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "August 2012", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Supportive Care", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}